FURVENT: Phase 3 trial of firmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004)

Lung Cancer. 2024 Dec 28:199:108066. doi: 10.1016/j.lungcan.2024.108066. Online ahead of print.

¹ Virginia Cancer Specialists Research Institute and Next Oncology, Fairfax, VA, United States.
² Division of Medical Oncology, Yonsei Cancer Center, Yonsei University of Medicine, Seoul, Republic of Korea.
³ Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain.
⁴ David Geffen School of Medicine, Division of Hematology and Oncology, UCLA, Los Angeles, CA, United States.
⁵ National Cancer Center Hospital East, Kashiwa, Japan.
⁶ Sarah Cannon Research Institute, Nashville, TN, United States.
⁷ Cancer Research Unit, Princess Margaret Cancer Centre, Toronto, Ontario, United States.
⁸ Division of Thoracic Oncology, European Institute of Oncology IRCCS, Milan, Italy.
⁹ Institut Gustave Roussy, Department of Medical Oncology, Villejuif, France.
¹⁰ The Royal Marsden, NHS Foundation Trust, London, United Kingdom.
¹¹ National Taiwan University Hospital, Taipei, Taiwan.
¹² Allist Pharmaceuticals, Shanghai, China.
¹³ ArriVent Biopharma, Burlingame, CA, United States.
¹⁴ Shanghai Pulmonary Hospital, Shanghai, China.

No abstract available

Keywords: Advanced; EGFR; EGFR-TKI; Ex20ins; Exon 20 insertions; Firmonertinib; Furmonertinib; Metastatic.

Publication types